ABVX vs ARWR
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ABVX · Abivax S.A.$85.73 ▲ 1.85%
ARWR · Arrowhead Pharmaceuticals$58.16 ▲ 1.22%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ABVX -19.2%
- ARWR +45.9%
Head to head
| Metric | ABVX | ARWR |
|---|---|---|
| Price | $85.73 | $58.16 |
| Change today | ▲ 1.85% | ▲ 1.22% |
| Market cap | $7.50B | $8.22B |
| Return, 3 months | -32.8% | -34.2% |
| Return, year to date | -36.4% | -12.4% |
| Return, 1 year | -18.6% | +48.3% |
| P/E (TTM) | – | – |
| P/B | 18.3 | 17.6 |
| P/E percentile vs own 5y | 57th | 31st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +171.0% |
| Net profit growth (YoY) | -142.6% | -0.1% |
| Gross margin | – | – |
| Operating margin | – | -33.8% |
| Net margin | – | -47.8% |
| Return on equity | -252.3% | -64.8% |
| Analyst target vs. price | +87.3% | +87.4% |
| Analyst buy share | 89% | 92% |
| RSI (14) | 42 | 40 |
| 30-day volatility | 49.2% | 37.2% |
| Max drawdown, 1 year | -50.1% | -37.6% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ARWR is the largest of the group by market value.
- ARWR has returned the most over the past year.
- ARWR has been the calmest stock over the last 30 days.